Franz joined LimmaTech as CEO in August 2023. He has held roles of increasing complexity and responsibility in the pharmaceutical industry for more than 20 years. Most recently, he was the CEO at CureVac SE following his tenures as Chief Corporate Officer and Chief Operating Officer. Before, Franz held the position of Vice President Operations and Chief Compliance Officer of SYGNIS Pharma AG, where he was responsible for the execution of M&A and capital market transactions. In the past, he held several management positions in the life sciences industry, including Vice President and General Counsel of LION Bioscience and General Counsel of Sirona Dental Systems. He holds a Doctor of Laws (LL.D.) degree and studied at the University of Saarbruecken, Catholic University of Leuven, and the University of Edinburgh.
As Managing Director and Vice President Clinical and Regulatory Affairs, Patricia is responsible for LimmaTech’s vaccine and therapeutic clinical programs. She joined GlycoVaxyn in 2014 in the Clinical Department and became part of LimmaTech’s Executive Management team in 2019. Prior to GlycoVaxyn, Patricia held various roles in clinical research in several biotech companies and CROs. In her over 10 years of industrial experience, she has acquired significant expertise in diverse vaccine and therapeutic clinical indications and has overseen studies ranging from Phase I to Phase IV. Patricia has a degree in Biochemistry from the National University of Cordoba, Argentina. After relocating to Switzerland, she received her PhD in Natural Science from the University of Zürich in 2010.
As Chief Scientific Officer, Michael is responsible for LimmaTech’s scientific development, focusing on pipeline development and operational R&D performance. Michael has a PhD in Biochemistry from the Swiss Federal Institute of Technology, Zurich (ETH Zurich) and developed a broad experience in the biotech industry. After university, he joined GlycoVaxyn AG to develop the company’s bioconjugation vaccine platform through its early stages. As VP Research and IP, he was responsible for the innovation of platform science and the collaboration with GSK that culminated in GlycoVaxyn’s acquisition by GlaxoSmithKline plc in February 2015. After that, Michael joined LimmaTech as a co-founder, and soon took the role of VP Business Strategy and IP to drive LimmaTech’s proprietary business, marking his journey into therapeutics. With the successful spin-out of the therapeutics assets into the newly formed company GlycoEra AG in January 2021, he moved back to his true scientific passion, vaccines.
As CFO, Paul is responsible for finance, administration, IT and human resources at LimmaTech. Most recently, he was CFO of GlycoVaxyn AG at the time of its acquisition by GlaxoSmithKline plc in February 2015. Previously, Paul was the Chief Financial Officer of Source Capital AG, a FINMA-regulated algorithmic trading firm in Switzerland from 2012 to 2014. He was Managing Director of Investors Guaranty, a boutique private equity and venture capital firm, where he managed the financial and corporate development activities and served as a board member for the group’s portfolio companies from 2001 to 2012. Prior to 2001, he worked for SEI Investments Inc. in the United States and Switzerland in various corporate finance positions focusing on the company’s new ventures. Paul holds a B.S. in finance from LaSalle University in Philadelphia and an MBA from Villanova University in Pennsylvania (USA).